These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

912 related items for PubMed ID: 19229766

  • 1. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 2. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [Abstract] [Full Text] [Related]

  • 4. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Dec; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 5. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 6. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 7. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [Abstract] [Full Text] [Related]

  • 8. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 9. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 10. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 11. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Emery P.
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [Abstract] [Full Text] [Related]

  • 13. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
    de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K.
    Scand J Rheumatol; 2010 Nov; 39(1):19-25. PubMed ID: 20132066
    [Abstract] [Full Text] [Related]

  • 14. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
    Liang GC, Cordero M, Dyer A, Chang RW.
    J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 16. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 18. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Nikolaisen C, Rekvig OP, Nossent HC.
    Scand J Rheumatol; 2005 Dec; 34(4):269-76. PubMed ID: 16195159
    [Abstract] [Full Text] [Related]

  • 19. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.